375 related articles for article (PubMed ID: 9848068)
1. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
Hitzer S; Bialasiewicz AA; Richard G
Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
[TBL] [Abstract][Full Text] [Related]
2. [Distribution of melanoma-associated antigens (HMB 45 and S 100) in benign and malignant melanocytic tumors of the conjunctiva].
Steuhl KP; Rohrbach JM; Knorr M
Klin Monbl Augenheilkd; 1991 Sep; 199(3):187-91. PubMed ID: 1753671
[TBL] [Abstract][Full Text] [Related]
3. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
4. Incidence of melanocytic lesions of the conjunctiva in a review of 10 675 ophthalmic specimens.
Novais GA; Fernandes BF; Belfort RN; Castiglione E; Cheema DP; Burnier MN
Int J Surg Pathol; 2010 Feb; 18(1):60-3. PubMed ID: 18611943
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical studies of conjunctival nevi and melanomas.
Jakobiec FA; Bhat P; Colby KA
Arch Ophthalmol; 2010 Feb; 128(2):174-83. PubMed ID: 20142539
[TBL] [Abstract][Full Text] [Related]
6. The initial steps of tumor progression in melanocytic lineage: a histochemical approach.
Wollina U; Kilian U; Henkel U; Schaarschmidt H; Knopf B
Anticancer Res; 1991; 11(4):1405-14. PubMed ID: 1746897
[TBL] [Abstract][Full Text] [Related]
7. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
8. [Comparative study of HMB-45 monoclonal antibody uptake on various benign and malignant melanocytic lesions].
Lampert A; Thomine E; Lauret P; Hemet J
Ann Pathol; 1993; 13(2):100-7. PubMed ID: 8363667
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
10. Primary acquired melanosis of the conjunctiva is melanoma in situ.
Ackerman AB; Sood R; Koenig M
Mod Pathol; 1991 Mar; 4(2):253-63. PubMed ID: 2047386
[TBL] [Abstract][Full Text] [Related]
11. Differential immunoreactivity of melanocytic lesions of the conjunctiva.
Sharara NA; Alexander RA; Luthert PJ; Hungerford JL; Cree IA
Histopathology; 2001 Oct; 39(4):426-31. PubMed ID: 11683945
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotypic markers to differentiate between benign and malignant melanocytic lesions.
Keijser S; Missotten GS; Bonfrer JM; de Wolff-Rouendaal D; Jager MJ; de Keizer RJ
Br J Ophthalmol; 2006 Feb; 90(2):213-7. PubMed ID: 16424536
[TBL] [Abstract][Full Text] [Related]
14. HMB-45 may be a more sensitive maker than S-100 or Melan-A for immunohistochemical diagnosis of primary oral and nasal mucosal melanomas.
Yu CH; Chen HH; Liu CM; Jeng YM; Wang JT; Wang YP; Liu BY; Sun A; Chiang CP
J Oral Pathol Med; 2005 Oct; 34(9):540-5. PubMed ID: 16138892
[TBL] [Abstract][Full Text] [Related]
15. Distribution and colocalization of markers for proliferation, invasion, motility and neoangiogenesis in benign melanocytic naevi and malignant melanomas.
Fröhlich E; Mack AF; Garbe C; Klessen C
Br J Dermatol; 2005 Dec; 153(6):1159-65. PubMed ID: 16307652
[TBL] [Abstract][Full Text] [Related]
16. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of tumor-associated lymphangiogenesis in malignant melanomas of the conjunctiva.
Heindl LM; Hofmann-Rummelt C; Adler W; Bosch JJ; Holbach LM; Naumann GO; Kruse FE; Cursiefen C
Ophthalmology; 2011 Dec; 118(12):2351-60. PubMed ID: 21835473
[TBL] [Abstract][Full Text] [Related]
18. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
19. Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.
Elder DE; Rodeck U; Thurin J; Cardillo F; Clark WH; Stewart R; Herlyn M
Cancer Res; 1989 Sep; 49(18):5091-6. PubMed ID: 2548711
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of DNA ploidy and degree of DNA abnormality in benign and malignant melanocytic lesions of the skin using video imaging.
Pilch H; Günzel S; Schäffer U; Tanner B; Heine M
Cancer; 2000 Mar; 88(6):1370-7. PubMed ID: 10717619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
